Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT04254978
Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)
- NCT04254978 ↗
- Completed
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
- Focused
We haven't built an HCP commentary report on NCT04254978 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04254978 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients With Essential Thrombocythemia
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Essential Thrombocythemia
- Interventions
- Bomedemstat
- Arms
- Bomedemstat · Experimental
- Enrollment
- 73
- Primary outcomes
- Number of Participants Who Experienced an Adverse Event (AE)
- Number of Participants Who Discontinued Study Treatment Due to an AE
- Percentage of Participants With Platelet Count ≤400 k/μL at Day 169
- Sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
- Start
- Sep 8, 2020
- Primary completion
- Mar 23, 2023
- Results posted
- Yes
- Registry record
- NCT04254978 · updated May 4, 2026
Publications
linked from the registry- Gill H, Palandri F, Ross DM, Gothert JR, Cochrane T, Larsen SR, Halpern AB, Shortt J, Rossetti JM, Liang J, Marchetti M, Wilson AJ, Innes AJ, Hanna M, Vianelli N, Stevenson WS, Vannucchi AM, Kleppe M, Flynn J, Natsoulis G, Harrison CN, Rienhoff HY Jr. Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia. Blood Adv. 2026 May 26;10(10):3494-3504. doi: 10.1182/bloodadvances.2025017575. PubMed 41758981